← Back to Search

ACT-LCS Therapy for Lung Cancer

N/A
Waitlist Available
Led By Linda Garland, MD
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with or treated for Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) within the prior 12 months.
Scores of 37.5 on the Lung Cancer Stigma Inventory (LCSI) screening measure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 months
Awards & highlights

Study Summary

This study is evaluating whether a novel psychotherapy intervention may help reduce stigma in lung cancer patients.

Eligible Conditions
  • Lung Cancer
  • Lung Cancer Stigma
  • Social Stigma
  • Stigmatization
  • Acceptance

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of individuals who consent to the intervention
Number of sessions that each consented patient attended

Trial Design

1Treatment groups
Experimental Treatment
Group I: ACT-LCS TherapyExperimental Treatment1 Intervention
Intervention is psychosocial counseling utilizing Acceptance and Commitment Therapy for Lung Cancer Stigma (ACT-LCS) as a patient-focused intervention to reduce the self-blame, guilt and inhibited disclosure associated with lung cancer stigma.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ACT-LCS Therapy
2018
N/A
~30

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor
512 Previous Clinical Trials
148,209 Total Patients Enrolled
Linda Garland, MDPrincipal InvestigatorUniversity of Arizona
3 Previous Clinical Trials
300 Total Patients Enrolled
Heidi Hamann, PhDPrincipal InvestigatorUniversity of Arizona

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~4 spots leftby Mar 2025